Dasotraline

Dasotraline
Systematic (IUPAC) name
(1R,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
Identifiers
CAS Number 675126-05-3 YesY
PubChem CID 9947999
ChemSpider 8123611 N
UNII 4D28EY0L5T YesY
ChEMBL CHEMBL3301595
Chemical data
Formula C16H15Cl2N
Molar mass 292.20 g·mol−1
 NYesY (what is this?)  (verify)

Dasotraline (INN)[1] (former developmental code name SEP-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is under development by Sunovion for clinical use.[2][3][4][5] The drug is no longer being developed for major depressive disorder (MDD), but is still under investigation for the treatment of attention-deficit hyperactivity disorder (ADHD) and eating disorders.[6][7] Structurally, dasotraline is a stereoisomer of desmethylsertraline, which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft) and an SNDRI similarly.

Side Effects

In phase I trials for ADHD, test subjects reported the following side effects:[8][9]

See also

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information (WHO) 27 (4). 2013. Retrieved 4 November 2014.
  2. Chen, Zhengming; Skolnick, Phil (2007). "Triple uptake inhibitors: therapeutic potential in depression and beyond". Expert Opinion on Investigational Drugs 16 (9): 1365–77. doi:10.1517/13543784.16.9.1365. PMID 17714023.
  3. DeLorenzo, C.; Lichenstein, S.; Schaefer, K.; Dunn, J.; Marshall, R.; Organisak, L.; Kharidia, J.; Robertson, B.; Mann, J. J.; Parsey, R. V. (2011). "SEP-225289 Serotonin and Dopamine Transporter Occupancy: A PET Study". Journal of Nuclear Medicine 52 (7): 1150–5. doi:10.2967/jnumed.110.084525. PMC 3856248. PMID 21680689.
  4. Ziegler, L.; Küffer, G.; Euler, E.; Wilhelm, K. (1990). "Arthrographische Darstellung von Ganglien im Handbereich" [Arthrographic imaging of ganglions of the hand]. RöFo (in German) 153 (2): 143–6. doi:10.1055/s-2008-1033352. PMID 2168068.
  5. Guiard, B.; Chenu, F.; El Mansari, M.; Blier, P. (2009). "P.1.c.059 Electrophysiological properties of the triple reuptake inhibitor SEP 225289 on monoaminergic neurons". European Neuropsychopharmacology 19: S285. doi:10.1016/S0924-977X(09)70419-5.
  6. Clinical trial number NCT02276209 for "Dasotraline Adult ADHD Study" at ClinicalTrials.gov
  7. http://adisinsight.springer.com/drugs/800023450[]
  8. Koblan, Kenneth S; Hopkins, Seth C; Sarma, Kaushik; Jin, Fengbin; Goldman, Robert; Kollins, Scott H; Loebel, Antony (2015). "Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults". Neuropsychopharmacology 40 (12): 2745–52. doi:10.1038/npp.2015.124. PMID 25948101.
  9. http://www.additudemag.com/adhdblogs/19/11101.html[]

Further reading

Liming Shao Patent
Asymmetry Patent


This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.